Witryna1 wrz 2024 · Immune checkpoint inhibitors cause acute kidney injury (AKI), the most common being acute interstitial nephritis. •. In most cases, the acute interstitial … Witryna31 paź 2024 · In the 1,016 patients the analysis, 169 patients (17%) experienced AKI, 82 patients (8%) experienced sustained AKI, and 30 patients (3%) had potential immune checkpoint inhibitor–related AKI.
Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy
Sixteen patients developed AKI while on CPIs and required renal biopsies over the past 10 years at our institution. The characteristics of these patients, urine findings, AKI category, and associated renal pathology are summarized in Table 1. Most cases identified were white men (1 case was a Hispanic man, and 4 … Zobacz więcej The median time to development of AKI after starting a CPI was 14 weeks (range: 6–56 weeks). However, AKI occurred within 9 weeks with the use of the CTLA-4 inhibitor … Zobacz więcej IgA nephropathy developed in a patient receiving the combination therapy of ipilimumab and nivolumab and in a patient receiving pembrolizumab. Both patients had … Zobacz więcej Acute focal segmental necrotizing pauci -immune glomerulonephritis was noted in 3 cases, with nivolumab in 1 case, tremelimumab in 1 case, and nivolumab combined with ipilimumab, in 1 case. The patient on … Zobacz więcej Witryna11 paź 2024 · Many cases of AIN have been reported [12, 13], while immune-related glomerulonephritis or nephrotic syndrome have occasionally been described. To our knowledge, we report here the first case of renal granulomatous arteritis induced by ipilimumab. ... Crump M, Hogg D, et al. Nephrotic syndrome with Cancer … flywithchrist delmarva
Rechallenge patients with immune checkpoint inhibitors …
WitrynaBasic Principles for Management of Immune-related Adverse Events caused by Immunotherapy v5.0 Authors: Decatris MP & Chennupati J ... Basic Principles for … WitrynaImmune-related adverse events. Immune checkpoint inhibitors (e.g. ipilimumab, pembrolizumab, nivolumab, avelumab, atezolizumab) are forms of immunotherapy which work by stimulating the immune system (T-cells) to fight cancer and have been associated with substantial improvements in the prognosis of the disease. ... WitrynaImmune checkpoint inhibitors (ICIs) such as nivolumab and ipilimumab have improved outcomes in metastatic renal cell carcinoma (mRCC) patients, but they are also … green room long beach ca